These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32141259)

  • 41. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: A randomized, controlled, dose-ranging study.
    Bernstein DI; Gillespie M; Song S; Steinfeld J
    J Asthma; 2017 Aug; 54(6):559-569. PubMed ID: 27937064
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma.
    Cukier A; Jacob CM; Rosario Filho NA; Fiterman J; Vianna EO; Hetzel JL; Neis MA; Fiss E; Castro FF; Fernandes AL; Stirbulov R; Pizzichini E;
    Respir Med; 2013 Sep; 107(9):1330-8. PubMed ID: 23849625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Budesonide/formoterol pressurized metered-dose inhaler for patients with persistent asthma.
    Korenblat PE; Rosenwasser LJ
    Allergy Asthma Proc; 2010; 31(3):190-202. PubMed ID: 20482961
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
    Sher LD; Yiu G; Sakov A; Liu S; Caracta CF
    Allergy Asthma Proc; 2017 Sep; 38(5):343-353. PubMed ID: 28639542
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids.
    Kerwin EM; Gillespie M; Song S; Steinfeld J
    J Asthma; 2017 Jan; 54(1):89-98. PubMed ID: 27285965
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing the efficacy and safety of salmeterol/fluticasone pMDI versus its mono-components, other LABA/ICS pMDIs and salmeterol/fluticasone Diskus in patients with asthma.
    Mehta N; Aggarwal B; Gogtay J; Abdool-Gaffar S
    Expert Opin Drug Deliv; 2015 Jun; 12(6):963-75. PubMed ID: 25429610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma.
    Harrison LI; Novak CC; Needham MJ; Ratner P
    J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):245-52. PubMed ID: 21671752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study.
    Ramadan WH; Sarkis AT
    Chron Respir Dis; 2017 Aug; 14(3):309-320. PubMed ID: 28774201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metred-dose inhalers in patients with asthma treated with ICS/LABA.
    Park HS; Yoon D; Lee HY; Ban GY; Wan Yau Ming S; Jie JLZ; Carter V; Hardjojo A; Van Boven JFM; Price DB
    Respirology; 2019 Oct; 24(10):972-979. PubMed ID: 31038269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of mometasone furoate dry powder inhaler and fluticasone propionate dry powder inhaler in patients with moderate to severe persistent asthma requiring high-dose inhaled corticosteroid therapy: findings from a noninferiority trial.
    Harnest U; Price D; Howes T; Sussman G
    J Asthma; 2008 Apr; 45(3):215-20. PubMed ID: 18415829
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
    Martinez FJ; Rabe KF; Ferguson GT; Fabbri LM; Rennard S; Feldman GJ; Sethi S; Spangenthal S; Gottschlich GM; Rodriguez-Roisin R; Arora S; Siler TM; Siddiqui S; Darken P; Fischer T; Maes A; Golden M; Orevillo C; Reisner C
    Chest; 2017 Feb; 151(2):340-357. PubMed ID: 27916620
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Replacement of SFC-DPI with SFC-MDI exhaled through the nose improves eosinophilic chronic rhinosinusitis in patients with bronchial asthma.
    Kobayashi Y; Asako M; Yamamoto T; Yasuba H; Tomoda K; Kanda A
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):89-94. PubMed ID: 27879191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL; Boulet LP; Keith PK; Scott-Wilson CA; House KW; Dorinsky PM
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler.
    Lundback B; Alexander M; Day J; Hebert J; Holzer R; Van Uffelen R; Kesten S; Jones AL
    Respir Med; 1993 Nov; 87(8):609-20. PubMed ID: 8290745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology.
    Ferguson GT; Reisner C; Pearle J; DePetrillo P; Maes A; Martin UJ
    Pulm Pharmacol Ther; 2018 Apr; 49():67-74. PubMed ID: 29567116
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation.
    Rhee CK; van Boven JFM; Yau Ming SW; Park HY; Kim DK; Park HS; Ling JZJ; Yoo KH; Price DB
    J Allergy Clin Immunol Pract; 2019 Mar; 7(3):934-942. PubMed ID: 30292924
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative study of efficacy of salbutamol via metered dose inhaler with volumatic spacer and via dry powder inhaler, easyhaler, to nebulization in mild to moderate severity acute asthma exacerbation in childhood.
    Vangveeravong M
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S115-23. PubMed ID: 19253506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
    Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J
    Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.